BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Watson Pharmaceuticals, Inc. (WPI) Backs off from U.S. Plan for Stellar Pharmaceuticals Inc. (SLX.V)'s Uracyst Bladder Treatment After Study Does Not Meet Primary Endpoints


11/11/2010 6:58:02 AM

LONDON, ONTARIO--(Marketwire - November 10, 2010) - Stellar Pharmaceuticals Inc. (OTCBB: SLXCF) ("Stellar" or "the Company"), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, announced today that its U.S. licensee, Watson Pharma, Inc. (NYSE: WPI) ("Watson"), has finished a preliminary analysis of the data from Watson Ur008, a recently completed placebo controlled pilot study using the Company's Uracyst® product to treat interstitial cystitis/ painful bladder syndrome ("IC/PBS"). Watson has verbally informed the Company that Ur008 did not meet statistical significance in its primary endpoints and, as a result, Watson has elected not to proceed with Uracyst for the United States market.

Stellar has commenced a review and analysis of the Watson Ur008 study. This review and analysis will, among other things, seek to determine what role, if any, factors such as cohort size and patient selection criteria may have had with the study's unexpected overall results. The Company expects to base its go-forward strategy for Uracyst® in the United States upon the findings of that review and analysis.

In June 2009, Watson received conditional approval for an Investigational Device Exemption to conduct clinical work with Uracyst® from the U.S. Food and Drug Administration ("FDA") in the U.S. This conditional approval led to the commencement of Watson Ur008, a double blind, placebo-controlled, pilot clinical trial in 100 subjects at 20 clinical study centers in the U.S. Watson Ur008 was designed to strengthen the patient selection criteria for an anticipated larger pivotal study that, if successful, would support Watson's application with the FDA to obtain approval to market Uracyst in the United States.

About Stellar Pharmaceuticals Inc.

Stellar has developed and is marketing direct in Canada and in countries around the world through out-license agreements two products based on its core polysaccharide technology: NeoVisc®, for the treatment of osteoarthritis; and Uracyst®, its patented technology for treatment of interstitial cystitis/painful bladder syndrome, an inflammatory disease of the urinary bladder wall. Stellar also has in-licensing agreement for the distribution and sale of NMP22® BladderChek®, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer. For more information, please visit the company's website at www.stellarpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.


Contacts:
Company Contact
Stellar Pharmaceuticals Inc.
Peter Riehl
President & CEO
(519) 434-1540
corpinfo@stellarpharma.com

Investor Contact
Kilmer Lucas Inc.
Stephen Kilmer
President
(905) 690-2400 ext. 21
stephen@kilmerlucas.com



Read at News Release
Read at BusinessWeek
Read at Wall Street Journal
Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES